Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Intimation Of Schedule Of Investor/Analyst Meetings On August 2, 3 And 4, 2017

 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the details of investor/analyst meetings scheduled on August 2, 3 and 4, 2017. The schedule may undergo change due to exigencies on the part of Investors/Analysts/ Company. We also enclose the presentation to be used during the meetings. This is for your kind information and records.
01-08-2017
Bigul

Updates

 Intimation pursuant to Regulation 57(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for payment of Interest on Non-Convertible Debentures
28-07-2017

Jhunjhunwala's new investments in Jubilant Life Sciences and Jaiprakash Associates

 Rakesh Jhunjhunwala added two new stocks to his portfolio as per the latest shareholding data released for June 2017: Jubilant Life Sciences and Jaiprakash Associates. JP Associates has shot up in share price since the disclosure. Jubilant has also been gaining over the past week. Jubilant saw a revenue drop in its most recent quarter - Revenue fell by 1.75% to Rs. 1538.38 cr in Q1FY18, compared to the previous quarter but was up 9.81% YoY. Jhunjhunwala has also increased his stake in three stocks as of June 2017- pharma companies Aurobindo Pharma and Lupin Limited, and agrochemical company Rallis India. Among the five stocks Jhunjhunwala either newly purchased or increased his portfolio stake, his biggest total investment is in Lupin, where he holds Rs. 905.18 crore worth of shares.
20-07-2017
Bigul

Shareholding for the Period Ended June 30, 2017

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here
19-07-2017
Bigul

Updates

 Submission of copies of published Unaudited Consolidated Financial Results
19-07-2017
Bigul

Jubilant Life Sciences Q1 net down 12%

 Jubilant Life Sciences has posted a contracted net profit for the first quarter ended June 30, 2017. The pharmaceutical firm's net profit for the three-month period dipped by over 12 per cent at...
18-07-2017
Bigul

Unaudited Financial Results For The Quarter Ended June 30, 2017

 In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2017 were approved by the Board of Directors of the Company at its meeting held today at 1.30 p.m. and concluded at 2.20 p.m....
18-07-2017
Bigul

Updates

 Intimation pursuant to Regulation 50(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for interest payment on Non-Convertible Debentures
10-07-2017
Bigul

Statement Of Investor Complaints For The Quarter Ended June 30, 2017

 Statement of Investor Complaints for the Quarter ended June 30, 2017
07-07-2017
Bigul

Jubilant Life Sciences gets USFDA nod for anti-depressive drug

 Drug firm Jubilant Life Sciences today said its subsidiary has received final approval from the US health regulator for Bupropion Hydrochloride extended-release tablets, used for the treatment of...
06-07-2017
Next Page
Close

Let's Open Free Demat Account